Focused Orticumab Research for Treating Inflammation in Coronary Arteries
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.
Also called NCT06927739
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Abcentra
- Registry
-
NCT06927739
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Czechia, Hungary, Italy, Poland, Romania, Spain, Sweden, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT06927739. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-11 (actual); primary completion 2027-02-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Focused Orticumab Research for Treating Inflammation in Coronary Arteries
- Acronym
- FORTIFY
- Condition
- Acute Coronary Syndromes
- Condition
- Coronary Arterial Disease (CAD (coronary artery disease))
- Condition
- Inflammation
- Condition
- Heart Disease
- Condition
- Myocardial Infarct
- Condition
- Atherosclerotic Coronary Vascular Disease
- Intervention (Drug)
- Orticumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Abcentra
Record details
- Record id
cardio:ct-nct06927739- Content hash
a530bb064d834d4046c6d7f2ce1a41aef6070ef6cef748ec1e7c472f5401d45e